Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor, Adult × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 52 Cholangiocarcinoma 18 Carcinoma, Renal Cell 13 Biliary Tract Neoplasms 10 Stomach Neoplasms 8 Thyroid Neoplasms 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Neoplasms 6 Endometrial Neoplasms 6 Uterine Cervical Neoplasms 5 Recurrence 4 Ovarian Neoplasms 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Thyroid Carcinoma, Anaplastic 3 Thyroid Cancer, Papillary 3 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Neuroendocrine Tumors 3 Neoplasm Metastasis 3 Liver Neoplasms 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Advanced Biliary Tract Cancer 3 Adenocarcinoma, Follicular 3 Vulvar Neoplasms 2 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Pancreatic Neoplasms 2 Mesothelioma, Malignant 2

Interventions

tislelizumab 1 pembrolizumab 1 patritumab deruxtecan 1 leronlimab 1 lenvatinib 1 atezolizumab 1 Tiragolumab 1 Radiotherapy 1 Cryosurgery 1 3-amino-1-methyl-3-(4-(3-phenyl-5H- imidazo(1,2-c)pyrido(3,4-e)(1,3)oxazin-2-yl)phenyl)cyclobutanol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06032845 2025-02-27

CASTLE-11

Fudan University

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon ⚡